Bibliography (14):

1. Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes & Cardiovascular Disease

2. Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States

3. An overview of once-weekly glucagon-like peptide-1 receptor agonists—available efficacy and safety data and perspectives for the future

4. GLP-1R agonists for the treatment of obesity: a patent review (2015–present)

5. The Discovery and Development of Liraglutide and Semaglutide

6. What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know

7. The Doctor Prescribed an Obesity Drug. Her Insurer Called It ‘Vanity.’ Many insurance companies refuse to cover new weight loss drugs that their doctors deem medically necessary

8. https://www.wsj.com/health/heathcare/ozempic-mounjaro-weight-loss-drug-cost-32fc3555

9. Wikipedia Bibliography:

   1. https://en.wikipedia.org/wiki/Insulins  :

      https://en.wikipedia.org/wiki/Insulins

   2. https://en.wikipedia.org/wiki/Sodium-glucose_cotransporter_2_inhibitors  :

      https://en.wikipedia.org/wiki/Sodium-glucose_cotransporter_2_inhibitors

   3. https://en.wikipedia.org/wiki/Glucagon-like_peptide_1_agonists  :

      https://en.wikipedia.org/wiki/Glucagon-like_peptide_1_agonists

   4. https://en.wikipedia.org/wiki/Canagliflozin  :

      https://en.wikipedia.org/wiki/Canagliflozin

   5. https://en.wikipedia.org/wiki/Glucagon  :

      https://en.wikipedia.org/wiki/Glucagon

   6. Type 2 diabetes